Quick Comparison
| PEA (Palmitoylethanolamide) | Phenibut | |
|---|---|---|
| Half-Life | 1-2 hours (rapidly metabolized). Micronized forms have improved bioavailability | 5-6 hours |
| Typical Dosage | Standard: 300-1200 mg daily in 2-3 divided doses. Start at 600 mg daily. Micronized or ultra-micronized (um-PEA) forms have much better absorption. For chronic pain: 600 mg twice daily. For neuroinflammation: 400-600 mg twice daily. Effects build over 2-4 weeks. | Standard: 250-1000 mg on an empty stomach, no more than 1-2 times per week. NEVER use daily — tolerance and dependence develop within 3-5 days of consecutive use. Onset: 2-4 hours (slow). Do not exceed 2000 mg per occasion. |
| Administration | Oral (capsules, powder). Micronized (m-PEA) or ultra-micronized (um-PEA) forms preferred for bioavailability. | Oral (powder, capsules). Take on an empty stomach — food significantly reduces absorption. Slow onset (2-4 hours). |
| Research Papers | 10 papers | 10 papers |
| Categories |
Mechanism of Action
PEA (Palmitoylethanolamide)
PEA activates PPAR-alpha (peroxisome proliferator-activated receptor alpha), a nuclear receptor that heterodimerizes with RXR and downregulates pro-inflammatory gene expression (NF-kB target genes, COX-2, iNOS, TNF-alpha). It has an 'entourage effect' on the endocannabinoid system — it inhibits the degradation of anandamide by fatty acid amide hydrolase (FAAH) through allosteric modulation or substrate competition, and upregulates CB2 receptor expression on immune cells. This provides anti-inflammatory and analgesic effects without directly activating CB1/CB2. PEA also activates GPR55 and GPR119. It inhibits mast cell degranulation (reducing histamine, tryptase, and cytokine release) and reduces microglial activation in the brain (inhibiting Iba1 expression and pro-inflammatory cytokine production). PEA may also modulate TRPV1.
Phenibut
Phenibut is a structural analog of GABA with a phenyl ring that confers lipophilicity and allows blood-brain barrier penetration (unlike GABA itself). It acts as a GABA-B receptor agonist, binding to the GABAB1/GABAB2 heterodimer and activating Gi/o-coupled signaling (similar to baclofen), producing anxiolytic, muscle relaxant, and sedative effects through inhibition of adenylyl cyclase and modulation of potassium and calcium channels. Phenibut also blocks the alpha-2-delta-1 and alpha-2-delta-2 subunits of voltage-gated calcium channels, reducing presynaptic calcium influx and neurotransmitter release (similar to gabapentin/pregabalin). The dual mechanism—GABA-B agonism dampening inhibitory interneurons and calcium channel blockade reducing excitatory transmission—produces potent anti-anxiety and sleep-promoting effects. Rapid tolerance develops due to receptor downregulation.
Risks & Safety
PEA (Palmitoylethanolamide)
Common
Very well-tolerated — rare side effects. Mild GI discomfort.
Serious
None documented. Over 30 clinical trials confirm excellent safety profile.
Rare
Skin rash.
Phenibut
Common
Drowsiness, dizziness, nausea, tolerance with repeated use.
Serious
Physical dependence develops rapidly with daily use. Withdrawal can be severe and dangerous (anxiety, insomnia, psychosis, seizures). Respiratory depression when combined with alcohol or other CNS depressants.
Rare
Hallucinations, severe rebound anxiety, suicidal ideation during withdrawal.
Full Profiles
PEA (Palmitoylethanolamide) →
An endogenous fatty acid amide produced naturally in the body in response to pain and inflammation. PEA activates PPAR-alpha receptors and indirectly enhances endocannabinoid signaling without binding to cannabinoid receptors. It has strong evidence for neuropathic pain, neuroinflammation, and neuroprotection. Unlike anti-inflammatory drugs, it resolves inflammation rather than merely suppressing it.
Phenibut →
A GABA-B agonist and alpha-2-delta voltage-gated calcium channel blocker developed in Russia for anxiety, insomnia, and PTSD. It crosses the blood-brain barrier (unlike GABA supplements) and produces potent anxiolytic and social confidence effects. However, it carries significant addiction and withdrawal risks — tolerance develops within days of daily use, and withdrawal can be severe.